Table 2.
Non-enhancement (%) | Mild enhancement (%) | Marked enhancement (%) | |
---|---|---|---|
Group ACU | 0 | 3 (9.7%) | 28 (90.3%) |
Group CHR | 0 | 3 (23.1%) | 10 (76.9%) |
Group NON | 8 (28.6%) | 6 (21.4%) | 14 (50%) |
Group ACU, the acute/sub-acute phase culprit plaque group; Group CHR, the chronic-phase culprit plaque group; Group NON, the non-culprit plaque group.